Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of C134 in Recurrent Malignant Glioma
NCT03657576Phase 1Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Sep 2019
- Primary completion
- Oct 2024
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C134 in glioblastoma multiforme (GBM), anaplastic astrocytoma (AA) and Gliosarcoma (GS), sponsored by University of Alabama at Birmingham. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Sep 2019; status: completed.
02
Drugs
C134
03
Conditions
glioblastoma multiforme (GBM)anaplastic astrocytoma (AA)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT03657576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03657576.